Usmani Highlights the Role of Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma

0 Mga view· 09/04/23
OncLive® On Air
OncLive® On Air
0 Mga subscriber
0
Sa

Dr Usmani discusses the integration of elranatamab, talquetamab, and telcistamab into the management of relapsed/refractory multiple myeloma, common adverse effects and recommended supportive care measures, and ongoing research that may help clarify their role in the paradigm.

Magpakita ng higit pa

 0 Mga komento sort   Pagbukud-bukurin Ayon


Susunod